Spots Global Cancer Trial Database for Conversion From Fast Acting Oral Opioids to Abstral®
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Conversion From Fast Acting Oral Opioids to Abstral®
Official Title: Conversion From Fast Acting Oral Opioids to Abstral® (SL Fentanyl) in Opioid Tolerant Cancer Patients With Breakthrough Pain
Study ID: NCT01315886
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate safety and efficacy when using a novel dose conversion strategy to switch from immediate release oral opioids to sublingual (SL) fentanyl (Abstral) for treatment of breakthrough cancer pain (BTcP).
Detailed Description: The study aims to show that in the advanced stage of cancer the individual patient already on high doses of BTcP medication will benefit from starting treatment on a higher first dose of SL fentanyl thus reducing the number of dosing steps with insufficient pain relief.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Smärtavdelning B42, Anestesikliniken Karolinska University Hospital, Huddinge, Stockholm, , Sweden
Contact Details
Name: Anders Pettersson, MD, PhD
Affiliation: Orexo AB
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
